Amarin Corp Plc\Uk
$5.61B- Market cap
- $5.73B
- Debt
- +$177.39M
- Cash
- −$302.59M
Capital structure 97% equity / 3% debt · EV / Revenue 26.25x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt cap
Decision snapshot: AMRN stock price at premium vs QCOM $13.65 current versus $2.06 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at QCOM's multiple
Implied fair value · at AMRN's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: AMRN FY 2025 (ended Dec 31, 2025) · QCOM FY 2025 (ended Sep 28, 2025). Fiscal years are not aligned.
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 97% equity / 3% debt · EV / Revenue 26.25x
Capital structure 92% equity / 8% debt · EV / Revenue 4.11x · EV / EBITDA 12.17x
QCOM carries the larger enterprise value at $181.86B against $5.61B; QCOM trades on the lower EV / Revenue multiple (4.11x vs 26.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
AMARIN CORP PLC\UK · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
QUALCOMM INC/DE · implied price per share
Bear
$150.35
Base
$182.35
Bull
$226.48
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.39x
0.70x
Net debt / EBITDA
Leverage against operating earnings
3.79x
0.31x
Cash and equivalents
Liquid reserves on the balance sheet
$302.59M
$10.16B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LIGAND PHARMACEUTICALS INC
AMRN vs LGND
Harmony Biosciences Holdings, Inc.
AMRN vs HRMY
SUPERNUS PHARMACEUTICALS, INC.
AMRN vs SUPN
Viatris Inc
AMRN vs VTRS
Organon & Co.
AMRN vs OGN
INCYTE CORP
AMRN vs INCY
Broadcom Inc.
AMRN vs AVGO
INTEL CORP
AMRN vs INTC
NVIDIA CORP
AMRN vs NVDA
TEXAS INSTRUMENTS INC
AMRN vs TXN
ADVANCED MICRO DEVICES INC
AMRN vs AMD
Qorvo, Inc.
AMRN vs QRVO
$177.39M
$14.81B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe AMRN can materially improve revenue growth and convert its 56.6% gross margin into positive operating margins, then avoid adding at current levels; otherwise, the data argues for caution because the stock trades at a large premium to QCOM while fundamentals remain materially weaker.
AMRN's current price of $16.39 sits far above QCOM-implied value of $2.16, implying 86.8% downside versus QCOM-based valuation. The gap is driven by AMRN's much higher revenue and earnings multiples than QCOM despite materially weaker operating performance.
Supporting Metrics